Wen Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wen Xu has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
Hongrong Deng
Department of Endocrinology and Metabolism The Third Affiliated Hospital of Sun Yat‐sen University, Guangdong Provincial Key Laboratory of Diabetology Guangzhou China
23 shared publications- Jinhua Yan
Department of Endocrinology and Metabolism The Third Affiliated Hospital of Sun Yat‐sen University, Guangdong Provincial Key Laboratory of Diabetology Guangzhou China
21 shared publications - Daizhi Yang
Department of Endocrinology and Metabolism The Third Affiliated Hospital of Sun Yat‐sen University, Guangdong Provincial Key Laboratory of Diabetology Guangzhou China
15 shared publications - Xubin Yang
Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
14 shared publications - Jianping Weng
Department of Endocrinology, Institute of Endocrine and Metabolic Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of China, Hefei, Anhui, 230001, China
13 shared publications Xubin Yang
Department of Endocrinology and Metabolism, Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology
12 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8297
Effects of Intensive Insulin Therapy Within One Week on Glycemic Control and β-Cell Function in Patients with T2DM
Objective: To evaluate the impact of intensive insulin therapy (IIT) within 1 week on glycemic control and β-cell function indices in patients with type 2 diabetes mellitus (T2DM). Methods: This retrospective study included 726 patients with T2DM who underwent continuous subcutaneous insulin infusion within 1 week. Patients were divided into three groups based on disease duration: short (≤1 year), medium (>1 and p < 0.01 for both). HOMA-β, 30 min insulinogenic index, 30 min disposition index, and insulin secretion sensitivity index-2 markedly improved from baseline [37.69 (41.03) VS. 32.40 (46.06), 3.16 (3.97) VS. 2.12 (3.51), 336.85 (397.05) VS. 188.93 (263.45), and 185.92 (122.89) VS. 120.81 (90.12), respectively] (p < 0.01 for all). Insulin sensitivity, measured by HOMA-IR and Matsuda index, significantly improved (p < 0.01 for both). Significantly greater improvements in glycemic control and β-cell function measures were observed in patients with a shorter diabetes duration. Age, duration of diabetes, BMI, HbA1c, duration of IIT, and time in range were significantly associated with improvements in β-cell function indices. Conclusions: IIT within 1 week was associated with improved glycemic control and β-cell function indices in T2DM patients, with the most pronounced benefits observed in those with a shorter disease duration.
- 25 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8297
Open AccessEffects of Intensive Insulin Therapy Within One Week on Glycemic Control and β-Cell Function in Patients with T2DM
Objective: To evaluate the impact of intensive insulin therapy (IIT) within 1 week on glycemic control and β-cell function indices in patients with type 2 diabetes mellitus (T2DM). Methods: This retrospective study included 726 patients with T2DM who underwent continuous subcutaneous insulin infusion within 1 week. Patients were divided into three groups based on disease duration: short (≤1 year), medium (>1 and p < 0.01 for both). HOMA-β, 30 min insulinogenic index, 30 min disposition index, and insulin secretion sensitivity index-2 markedly improved from baseline [37.69 (41.03) VS. 32.40 (46.06), 3.16 (3.97) VS. 2.12 (3.51), 336.85 (397.05) VS. 188.93 (263.45), and 185.92 (122.89) VS. 120.81 (90.12), respectively] (p < 0.01 for all). Insulin sensitivity, measured by HOMA-IR and Matsuda index, significantly improved (p < 0.01 for both). Significantly greater improvements in glycemic control and β-cell function measures were observed in patients with a shorter diabetes duration. Age, duration of diabetes, BMI, HbA1c, duration of IIT, and time in range were significantly associated with improvements in β-cell function indices. Conclusions: IIT within 1 week was associated with improved glycemic control and β-cell function indices in T2DM patients, with the most pronounced benefits observed in those with a shorter disease duration.
- 17 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11545-11555
Early Use of Automated Insulin Delivery With Telehealth Support in People Recently Diagnosed With Type 1 Diabetes: One‐Year Outcomes From a Prospective Observational Study
Aims: This study aims to evaluate the effectiveness and safety of early AID initiation combined with a telehealth support programme in individuals recently diagnosed with type 1 diabetes (T1D) in mainland China. Materials and Methods: This prospective, single‐arm, observational study sequentially enrolled individuals within 3 months of T1D diagnosis who initiated self‐funded AID system with the AndroidAPS algorithm. Participants received a structured e‐learning and personalised telehealth consultation during the first month followed by regular virtual follow‐up. Glycaemic outcomes were assessed at 1, 3, 6, and 12 months after AID initiation. Safety outcomes included severe hypoglycaemia (SH) and diabetic ketoacidosis (DKA). Results: A total of 126 participants completed at least 3 months of follow‐up. Median age was 13.6 (8.9, 27.4) years and median diabetes duration was 0.9 (0.5, 1.7) months. Percentage of time in range 3.9–10.0 mmol/L (TIR) was 85.2% (80.4, 90.7) during the first month and remained stable through 12 months. Among individuals with prior CGM data ( N = 93), TIR increased from 70.0% (58.6, 80.2) before AID initiation to 84.8% (79.9, 90.4) at 1 month and remained similar at 12 months. HbA1c (when available, n = 95) decreased from 10.0% (8.0, 13.4) [86 mmol/mol (64, 123)] at diagnosis to 6.3% (6.0, 6.8) [45 mmol/mol (42, 51)] at 12 months. No episodes of SH or DKA were reported. However, by the latest data update (August, 2026), the AID discontinuation rate was 35.7% ( N = 45), which was mainly due to financial barriers (55.2%). Conclusions: Early self‐funded AID initiation, supported by telehealth support, was associated with rapid and sustained glycaemic improvement in those recently diagnosed with T1D. Financial burden was the key challenge for consistent use of this advanced diabetes technology. Trail Registration: NCT06081231.
- 17 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11545-11555
Early Use of Automated Insulin Delivery With Telehealth Support in People Recently Diagnosed With Type 1 Diabetes: One‐Year Outcomes From a Prospective Observational Study
Aims: This study aims to evaluate the effectiveness and safety of early AID initiation combined with a telehealth support programme in individuals recently diagnosed with type 1 diabetes (T1D) in mainland China. Materials and Methods: This prospective, single‐arm, observational study sequentially enrolled individuals within 3 months of T1D diagnosis who initiated self‐funded AID system with the AndroidAPS algorithm. Participants received a structured e‐learning and personalised telehealth consultation during the first month followed by regular virtual follow‐up. Glycaemic outcomes were assessed at 1, 3, 6, and 12 months after AID initiation. Safety outcomes included severe hypoglycaemia (SH) and diabetic ketoacidosis (DKA). Results: A total of 126 participants completed at least 3 months of follow‐up. Median age was 13.6 (8.9, 27.4) years and median diabetes duration was 0.9 (0.5, 1.7) months. Percentage of time in range 3.9–10.0 mmol/L (TIR) was 85.2% (80.4, 90.7) during the first month and remained stable through 12 months. Among individuals with prior CGM data ( N = 93), TIR increased from 70.0% (58.6, 80.2) before AID initiation to 84.8% (79.9, 90.4) at 1 month and remained similar at 12 months. HbA1c (when available, n = 95) decreased from 10.0% (8.0, 13.4) [86 mmol/mol (64, 123)] at diagnosis to 6.3% (6.0, 6.8) [45 mmol/mol (42, 51)] at 12 months. No episodes of SH or DKA were reported. However, by the latest data update (August, 2026), the AID discontinuation rate was 35.7% ( N = 45), which was mainly due to financial barriers (55.2%). Conclusions: Early self‐funded AID initiation, supported by telehealth support, was associated with rapid and sustained glycaemic improvement in those recently diagnosed with T1D. Financial burden was the key challenge for consistent use of this advanced diabetes technology. Trail Registration: NCT06081231.
- 27 August 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10625-10635
Real‐World Glycemic Outcomes of Open‐Source Automated Insulin Delivery During 12 Months Among People With Type 1 Diabetes Across Age Groups
Aims: To assess glycemic outcomes across different age groups and explore factors associated with glycemic target achievement during 12‐months open‐source android artificial pancreas (AAPS) use among people with type 1 diabetes (T1D). Methods: This study included people with T1D who had used AAPS continuously for 12 months. Glycemic outcomes were assessed at 3, 6, and 12 months post‐initiation by age stratification (2–7, 8–12, 13–18, 19–30, 31–45, and > 45 years). Factors associated with achieving composite target of time in range of 70–180 mg/dL[TIR] > 70% and time below range of 70 mg/dL [TBR70] < 4% at 12 months were explored. Results: A total of 190 individuals were enrolled, with median age of 26.1 (11.9, 36.7) years and T1D duration of 2.1 (0.2, 8.4) years. Mean TIR remained high and stable during 12 months (79.9% ± 11.8%, 77.8% ± 13.9%, and 77.2% ± 13.5% at 3, 6, and 12 months), with TBR70 of 3.8 (1.9, 6.1)%, 3.3 (1.6, 5.8)% and 3.6 (2.0, 6.6)% respectively. However, outcomes varied by age. At 12 months, TIR was 72.8% ± 15.5% in 13–18 years group, with TBR70 of 4.2 [2.7, 6.3]%, while > 45 years group had TIR of 78.9% ± 11.8% and relatively less hypoglycemia (TBR70, 2.5 [1.2, 5.9]%). In exploratory analyses, higher target achievement rate of the composite target was associated with longer time in automation in adults (OR 1.04; p = 0.03) and higher meal announcement frequency in paediatrics under 18 years (OR 1.35; p < 0.01). Conclusions: Open‐source AAPS achieved sustained glycemic improvement across age groups in T1D people. Age‐related differences in influencing factors highlight the need for age‐tailored strategies to optimise long‐term outcomes.
- 27 August 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10625-10635
Real‐World Glycemic Outcomes of Open‐Source Automated Insulin Delivery During 12 Months Among People With Type 1 Diabetes Across Age Groups
Aims: To assess glycemic outcomes across different age groups and explore factors associated with glycemic target achievement during 12‐months open‐source android artificial pancreas (AAPS) use among people with type 1 diabetes (T1D). Methods: This study included people with T1D who had used AAPS continuously for 12 months. Glycemic outcomes were assessed at 3, 6, and 12 months post‐initiation by age stratification (2–7, 8–12, 13–18, 19–30, 31–45, and > 45 years). Factors associated with achieving composite target of time in range of 70–180 mg/dL[TIR] > 70% and time below range of 70 mg/dL [TBR70] < 4% at 12 months were explored. Results: A total of 190 individuals were enrolled, with median age of 26.1 (11.9, 36.7) years and T1D duration of 2.1 (0.2, 8.4) years. Mean TIR remained high and stable during 12 months (79.9% ± 11.8%, 77.8% ± 13.9%, and 77.2% ± 13.5% at 3, 6, and 12 months), with TBR70 of 3.8 (1.9, 6.1)%, 3.3 (1.6, 5.8)% and 3.6 (2.0, 6.6)% respectively. However, outcomes varied by age. At 12 months, TIR was 72.8% ± 15.5% in 13–18 years group, with TBR70 of 4.2 [2.7, 6.3]%, while > 45 years group had TIR of 78.9% ± 11.8% and relatively less hypoglycemia (TBR70, 2.5 [1.2, 5.9]%). In exploratory analyses, higher target achievement rate of the composite target was associated with longer time in automation in adults (OR 1.04; p = 0.03) and higher meal announcement frequency in paediatrics under 18 years (OR 1.35; p < 0.01). Conclusions: Open‐source AAPS achieved sustained glycemic improvement across age groups in T1D people. Age‐related differences in influencing factors highlight the need for age‐tailored strategies to optimise long‐term outcomes.
- Open Access
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1784299
A case report and literature review of proton pump inhibitors inducing insulin autoimmune syndrome
Background: Insulin autoimmune syndrome (IAS) is an autoimmune endocrine disorder characterized by hyperinsulinemia, positive insulin autoantibodies (IAA), and hypoglycemia. IAS was previously thought to be induced by drugs containing thiol groups. Objective: We describe a case highlighting that IAS may be temporally associated with a proton pump inhibitor (PPI) exposure. This article reports a patient who took beraprost sodium, clopidogrel, atorvastatin calcium, and the PPI pantoprazole and was subsequently diagnosed with IAS, presenting with a high IAA level, refractory hypoglycemia, and markedly elevated insulin levels. The patient’s hypoglycemic episodes were ultimately relieved after discontinuation of the PPI, accompanied by a gradual decrease in the IAA level to the normal range. Key findings: HLA analysis revealed HLA-DRB1*0403, DQB1*0302, and DQA1*0301, indicating the patient’s genetic susceptibility to IAS, which was possibly triggered by the PPI. Clinical relevance: This case report may alert clinicians to possible PPI-associated IAS, helping to avoid misdiagnosis and enable patients to receive timely treatment.
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1784299
Open AccessA case report and literature review of proton pump inhibitors inducing insulin autoimmune syndrome
Background: Insulin autoimmune syndrome (IAS) is an autoimmune endocrine disorder characterized by hyperinsulinemia, positive insulin autoantibodies (IAA), and hypoglycemia. IAS was previously thought to be induced by drugs containing thiol groups. Objective: We describe a case highlighting that IAS may be temporally associated with a proton pump inhibitor (PPI) exposure. This article reports a patient who took beraprost sodium, clopidogrel, atorvastatin calcium, and the PPI pantoprazole and was subsequently diagnosed with IAS, presenting with a high IAA level, refractory hypoglycemia, and markedly elevated insulin levels. The patient’s hypoglycemic episodes were ultimately relieved after discontinuation of the PPI, accompanied by a gradual decrease in the IAA level to the normal range. Key findings: HLA analysis revealed HLA-DRB1*0403, DQB1*0302, and DQA1*0301, indicating the patient’s genetic susceptibility to IAS, which was possibly triggered by the PPI. Clinical relevance: This case report may alert clinicians to possible PPI-associated IAS, helping to avoid misdiagnosis and enable patients to receive timely treatment.
- Open Access
- 4 April 2026
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
Continuous glucose monitoring-derived glycemic variability and low skeletal muscle mass in middle-aged and older adults with type 2 diabetes mellitus: an analysis using AWGS 2025 criteria
The impact of glycemic variability (GV) on muscle mass in type 2 diabetes mellitus (T2DM) remains unclear under the updated Asian Working Group for Sarcope
- 4 April 2026
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
Open AccessContinuous glucose monitoring-derived glycemic variability and low skeletal muscle mass in middle-aged and older adults with type 2 diabetes mellitus: an analysis using AWGS 2025 criteria
The impact of glycemic variability (GV) on muscle mass in type 2 diabetes mellitus (T2DM) remains unclear under the updated Asian Working Group for Sarcope
- Open Access
- 26 February 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria and diabetic kidney disease in adult type 2 diabetes: a cross-sectional study
To evaluate associations of the indicators of glycemic control, HbA1c, continuous glucose monitoring (CGM)-derived time in tight range (TITR; 70–140&
- 26 February 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Open AccessAssociations of time in tight range, time in range, and glycated hemoglobin with albuminuria and diabetic kidney disease in adult type 2 diabetes: a cross-sectional study
To evaluate associations of the indicators of glycemic control, HbA1c, continuous glucose monitoring (CGM)-derived time in tight range (TITR; 70–140&
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-10
Serum Uric Acid-to-Creatinine Ratio Is Independently Associated with Sudomotor Dysfunction in Type 2 Diabetes: A Cross-Sectional Study
Purpose: This study investigated the association between the serum uric acid-to-creatinine ratio (SUA/Cr) and sudomotor dysfunction in patients with type 2 diabetes mellitus. Patients and Methods: This was a single-center, inpatient, cross-sectional study. A total of 781 participants were classified into three tertiles based on their SUA/Cr. The electrochemical conductivity (ESC) of sweat obtained from the hands and feet was measured using SUDOSCAN to assess sudomotor function. Mean ESC values for the hands (HESC) and feet (FESC) were computed independently. Sudomotor dysfunction was defined as HESC or FESC ≤ 60 μS. Statistical analyses were performed using SPSS 25.0, involving one-way ANOVA, Kruskal–Wallis test, chi-square test, Spearman correlation coefficient, binary/multivariable logistic regression (with three adjusted models), and subgroup analysis, with statistical significance defined as p < 0.05. Results: The prevalence of sudomotor dysfunction in the first, second, and third tertiles of SUA/Cr was 65.0%, 57.6%, and 48.9%, respectively. Patients with lower SUA/Cr levels exhibited a markedly increased risk of sudomotor dysfunction compared to those with higher SUA/Cr levels (p < 0.001). After adjusting for potential confounders, the association between decreased SUA/Cr ratio and sudomotor dysfunction risk remained significant (OR=1.646, 95% CI: 1.088– 2.489, p = 0.018). Subgroup analyses by age, sex, glycated hemoglobin A1c, body mass index, and duration of diabetes confirmed the robustness of the relationship between SUA/Cr and the risk of diabetic peripheral neuropathy (all interactions p > 0.05). Conclusion: The SUA/Cr ratio is independently associated with sudomotor dysfunction in patients with type 2 diabetes mellitus.
- 1 February 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-10
Open AccessSerum Uric Acid-to-Creatinine Ratio Is Independently Associated with Sudomotor Dysfunction in Type 2 Diabetes: A Cross-Sectional Study
Purpose: This study investigated the association between the serum uric acid-to-creatinine ratio (SUA/Cr) and sudomotor dysfunction in patients with type 2 diabetes mellitus. Patients and Methods: This was a single-center, inpatient, cross-sectional study. A total of 781 participants were classified into three tertiles based on their SUA/Cr. The electrochemical conductivity (ESC) of sweat obtained from the hands and feet was measured using SUDOSCAN to assess sudomotor function. Mean ESC values for the hands (HESC) and feet (FESC) were computed independently. Sudomotor dysfunction was defined as HESC or FESC ≤ 60 μS. Statistical analyses were performed using SPSS 25.0, involving one-way ANOVA, Kruskal–Wallis test, chi-square test, Spearman correlation coefficient, binary/multivariable logistic regression (with three adjusted models), and subgroup analysis, with statistical significance defined as p < 0.05. Results: The prevalence of sudomotor dysfunction in the first, second, and third tertiles of SUA/Cr was 65.0%, 57.6%, and 48.9%, respectively. Patients with lower SUA/Cr levels exhibited a markedly increased risk of sudomotor dysfunction compared to those with higher SUA/Cr levels (p < 0.001). After adjusting for potential confounders, the association between decreased SUA/Cr ratio and sudomotor dysfunction risk remained significant (OR=1.646, 95% CI: 1.088– 2.489, p = 0.018). Subgroup analyses by age, sex, glycated hemoglobin A1c, body mass index, and duration of diabetes confirmed the robustness of the relationship between SUA/Cr and the risk of diabetic peripheral neuropathy (all interactions p > 0.05). Conclusion: The SUA/Cr ratio is independently associated with sudomotor dysfunction in patients with type 2 diabetes mellitus.
- 12 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 1750-1763
Impact of stepwise diabetes technology advances in older adults with type 1 diabetes: A systematic review and meta‐analysis of randomised trials
Objectives: To evaluate the efficacy and safety of advancing to higher levels of diabetes technology in older adults with type 1 diabetes (T1D). Methods: Web of Science, PubMed, Cochrane Library, and SCOPUS were searched. Inclusion criteria were randomised controlled trials (RCTs); aged ≥60 years with T1D. Interventions were pre‐specified into two domain comparisons: (1) Higher‐level insulin delivery (defined as automated insulin delivery, AID) versus lower‐level insulin delivery (comprising sensor‐augmented pumps and predictive low‐glucose suspend); and (2) Higher‐level glucose monitoring (defined as continuous glucose monitoring, CGM) versus lower‐level glucose monitoring (self‐monitoring of blood glucose). Co‐primary efficacy outcomes were time‐below‐range of p p = 0.002). Benefits were also observed for TBR 10.0 and >13.9 mmol/L, HbA1c, and glycemic variability (all p p p = 0.11). Conclusions: Advancing to higher‐level technologies for glucose monitoring and insulin delivery significantly and safely improve glycemic control in older adults with T1D. Physiological age alone should not be a primary barrier to prescribing these technologies, particularly for carefully selected older adults.
- 12 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 1750-1763
Impact of stepwise diabetes technology advances in older adults with type 1 diabetes: A systematic review and meta‐analysis of randomised trials
Objectives: To evaluate the efficacy and safety of advancing to higher levels of diabetes technology in older adults with type 1 diabetes (T1D). Methods: Web of Science, PubMed, Cochrane Library, and SCOPUS were searched. Inclusion criteria were randomised controlled trials (RCTs); aged ≥60 years with T1D. Interventions were pre‐specified into two domain comparisons: (1) Higher‐level insulin delivery (defined as automated insulin delivery, AID) versus lower‐level insulin delivery (comprising sensor‐augmented pumps and predictive low‐glucose suspend); and (2) Higher‐level glucose monitoring (defined as continuous glucose monitoring, CGM) versus lower‐level glucose monitoring (self‐monitoring of blood glucose). Co‐primary efficacy outcomes were time‐below‐range of p p = 0.002). Benefits were also observed for TBR 10.0 and >13.9 mmol/L, HbA1c, and glycemic variability (all p p p = 0.11). Conclusions: Advancing to higher‐level technologies for glucose monitoring and insulin delivery significantly and safely improve glycemic control in older adults with T1D. Physiological age alone should not be a primary barrier to prescribing these technologies, particularly for carefully selected older adults.
- Open Access
- 1 December 2025
- Published by KEAI Publishing in Medicine Plus
- Vol. 2 (4)
An unusual case of ectopic adrenocorticotrophic hormone syndrome and syndrome of inappropriate antidiuretic hormone secretion
- 1 December 2025
- Published by KEAI Publishing in Medicine Plus
- Vol. 2 (4)
Open AccessAn unusual case of ectopic adrenocorticotrophic hormone syndrome and syndrome of inappropriate antidiuretic hormone secretion